Cite
HARVARD Citation
Piaserico, S. et al. (2017). Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. Journal of the European Academy of Dermatology and Venereology. pp. 1853-1859. [Online].